Resource Center
Explore our library of helpful resources and scientific content on GP-2250.

Filter by Resource Type
- All
- Brochures
- Publications
- Videos
publication
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
Neuroendocrine carcinoma of the pancreas is a highly aggressive form of neu-roendocrine tumor associated with poor survival and increasing occurrence. GP-2250 is an emergent substance showing antineoplastic properties, especially in combination with Gemcitabine. This study was the first to evaluate the antineoplastic effects of GP-2250 on pancreatic neuroendocrine carcinoma.
Read More
video
Mechanism of Action Explainer Video
While cancer therapies are becoming increasingly specific to tumor and mutation type, a tumor and mutation agnostic yet targeted agent is of high therapeutic utility. Learn about GP-2250’s unique mechanism of action, which kills cancer cells by disrupting their energy metabolism.
Watch Video

brochure
New hope begins with novel science.
Panavance’s purpose is to give every patient the best possible chance to live a healthy and cancer-free life.
Read More

publication
Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo
German Cancer Congress, February 2016, Berlin, Germany (Abstract: Oncology Res Treat 2016; 39 (supply 1):1–175, abstract ID 0144, DOI: 10.1159/000444354)
Read More
publication
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.
2017, 17, 1-13. DOI: 10.1186/s12885-017-3204-x
Read More
publication
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer
ASCO Annual Meetings 2020, Chicago (Abstract: Journal of Clinical Oncology 38, no. 15_suppl. DOI: 10.1200/JCO.2020.38.15_suppl.e16750
Read More
publication
A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.
ASCO Gastrointestinal Cancers Symposium, Journal of Clinical Oncology 2022;40:4_suppl, TPS620-TPS620
Read More